• Prochlorperazine-Induced Neuroleptic Malignant Syndrome

  2026-08-19

  This case report highlights neuroleptic malignant syndrome after standard-dose prochlorperazine in an older adult, despite initially unremarkable laboratory findings. It shows why medication history, neurological examination, and clinical evolution may be more informative than creatine phosphokinase elevation alone when evaluating a drug-induced neurological emergency.

• Western Secondary Antibody Dilution Buffer K4115

  2026-08-19

  Western Secondary Antibody Dilution Buffer K4115 supports consistent secondary-antibody dilution for protein detection Western blot workflows. Its BSA-, detergent-, and stabilizer-containing formulation is designed for reducing non-specific antibody binding and improving antibody stability in assays, with documented reuse and storage specifications.

• Deferiprone for Iron-Stress Assay Design

  2026-08-18

  Deferiprone enables controlled iron depletion for studies of metabolism, proliferation, apoptosis, and inflammatory signaling. This practical guide translates enterocyte iron-stress findings into reproducible workflows while highlighting applications in cancer biology, doxorubicin injury, and cerebrovascular models.

• Dextran sulfate sodium salt in DSS Colitis Models

  2026-08-18

  Dextran sulfate sodium salt (MW 35000-45000) provides a practical route to model epithelial injury, inflammation, and mucosal repair in mice. This workflow connects DSS-induced barrier disruption with the GPR35-KLF5 repair circuitry, helping researchers distinguish anti-inflammatory activity from genuine epithelial healing.

• Resazurin Sodium Salt: Reading Metabolic Viability

  2026-08-17

  Resazurin sodium salt is a fluorogenic oxidation-reduction indicator that converts cellular reducing activity into a measurable fluorescence signal. This guide explains how to interpret that signal in glutamine-dependent fibrosis models, cancer cell line toxicity assessment, and scalable viability workflows without confusing metabolism with cell number.

• Tobramycin Workflows for Gram-Negative Research

  2026-08-17

  Build reproducible Tobramycin assays around aqueous handling, controlled inocula, and quantitative MIC readouts. This research-focused guide also shows how historical aminoglycoside comparisons can strengthen antibiotic resistance research and experimental troubleshooting.

• Deferiprone Workflows for Iron-Stress Research

  2026-08-16

  Build controlled iron-deficiency, oxidative-stress, and cytotoxicity assays with Deferiprone, a water-soluble chelator suited to mechanistic cell research. This guide connects enterocyte metabolomics with cancer biology, doxorubicin-protection studies, and exploratory neurovascular models while emphasizing dose, timing, and repletion controls.

• USP42 Promotes Breast Cancer by Blocking Apoptosis

  2026-08-15

  The reference study identifies USP42 as a pro-tumorigenic deubiquitinating enzyme in breast cancer and links its activity to suppression of JNK/p38-mediated apoptosis. By combining expression analysis, USP42 silencing, inhibitor rescue experiments, and xenograft modeling, the authors provide evidence that USP42 may be a useful mechanistic target for studying apoptosis resistance.

• Necrostatin 2: A Cell-Death Assay Lens

  2026-08-14

  Necrostatin 2 (Nec-2) enables targeted interrogation of necroptosis inhibition while exposing important distinctions between kinase signaling, membrane repair, and inflammatory tissue injury. This article uses TMEM16F-dependent Kupffer cell protection as a framework for designing more discriminating assays.

• Ceftolozane/Tazobactam: Mechanism, PK, and Evidence

  2026-08-14

  The reference review examines why ceftolozane/tazobactam was developed as an antipseudomonal cephalosporin/β-lactamase inhibitor combination for resistant gram-negative infections. Its central contribution is the integration of mechanism, microbiology, pharmacokinetics, pharmacodynamics, clinical evidence, and safety considerations into a framework for interpreting this agent in complicated intraabdominal and urinary tract infections.

• Haloprogin: Applied Antifungal Assay Workflows

  2026-08-13

  Haloprogin combines strong dermatophyte activity with reported effects against Candida and selected Gram-positive bacteria, making it useful for matrix-aware antimicrobial screening. This guide translates foundational serial-dilution and topical infection studies into practical workflows, formulation choices, and troubleshooting decisions.

• Nimbolide, RNF114, and PARP1 Trapping in BRCA Cancer

  2026-08-13

  Li and colleagues identified RNF114 as a PARylation-dependent E3 ubiquitin ligase that regulates PARP1 removal from DNA lesions. Their work shows that nimbolide inhibits this pathway, producing PARP1 and repair-factor trapping, synthetic lethality in BRCA-mutated models, and activity against models resistant to conventional PARP inhibitors.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody

  2026-08-12

  This reagent provides HRP-based detection of rabbit IgG primary antibodies in Western blot, ELISA, IHC, and IC workflows. It is intended for research use only; because no directly matched paper evidence is available for SKU K1223, assay-specific dilution, incubation, substrate, and sample compatibility must be established empirically.

• 2',7'-Dichlorofluorescein Diacetate for ROS

  2026-08-12

  2',7'-Dichlorofluorescein diacetate is a practical fluorescent ROS probe for measuring intracellular oxidative burden. This guide explains how to interpret its signal mechanistically when evaluating ROS-responsive nanocarriers and chemotherapy in pancreatic cancer models.

• Chronic E-64 Cathepsin Inhibition in Salt-Sensitive Rats

  2026-08-11

  This study tested whether chronic cysteine cathepsin inhibition modifies salt-sensitive hypertension, renal injury, or podocyte calcium signaling in Dahl salt-sensitive rats. E-64 exposure did not reduce blood pressure or albuminuria under the reported conditions, providing an important negative result and a framework for verifying inhibitor activity separately from disease-level outcomes.

16118 records 1/1075 page Next 12345 下5页 Last page